CMIC Raves about top level accreditation for Medidata’s EDC tech

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial

Japanese CRO CMIC says rising demand for Medidata Solutions’ Rave EDC system in Asia drove its decision to seek top-level provider status under the US firm’s accreditation scheme.

The Rave platform is a combined electronic data capture (EDC) and trial management system that is designed to help streamline the clinical study process.

Contract research organizations (CRO) wishing to offer the system to pharmaceutical and biotechnology customers do so by opting for one of four membership levels under Medidata’s ASPire to Win accreditation scheme.

CMIC has been granted “Rave Accredited Plus” status, the highest available accreditation, meaning it can offer clients the full range of related trial design, development and implementation services.

CMIC spokesman Hiroko Murata told Outsourcing-pharma that: “To attain this level, [CMIC] was required to participate in a number of training programmes andbe assessed by Medidata for [its] technical [capabilities].”

And after the technical level has been certified by Medidata, [the US firm] finally reviewed CMIC's operational processes including workflows and document management procedures​.”

Murata added that: “Since Rave is one of the top two EDC systems which are widely used, [achieving the highest level of partnership with Medidata] has great significance to [clients'] recognition of CMIC as an EDC specialist.”

He explained that CMIC, which became “Rave Accredited” in 2008, originally joined the programme “because of Rave’s ease of use and rich functionality as well as its multi-language support that lends itself well to Asia’s multinational population​.”

In a press release Graham Bunn, VP for global CRO partnerships at Medidata, said: “We’re thrilled to deepen our relationship with CMIC… and to further expand our joint presence in the Asia-Pacific region​.”

He went on to say that “Sponsors of clinical research across Asia will further benefit from CMIC’s extensive clinical experience and in-depth Rave expertise​.”

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us


View more